Elissar Moujaess

441 total citations
9 papers, 318 citations indexed

About

Elissar Moujaess is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Elissar Moujaess has authored 9 papers receiving a total of 318 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Infectious Diseases. Recurrent topics in Elissar Moujaess's work include COVID-19 and healthcare impacts (2 papers), Healthcare cost, quality, practices (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Elissar Moujaess is often cited by papers focused on COVID-19 and healthcare impacts (2 papers), Healthcare cost, quality, practices (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Elissar Moujaess collaborates with scholars based in Lebanon. Elissar Moujaess's co-authors include Hampig Raphaël Kourié, Marwan Ghosn, Joseph Kattan, Fadi Haddad, Fadi El Karak, Roland Eid, Tarek Assi, May Fakhoury, Chris Labaki and Georges Chahine and has published in prestigious journals such as Critical Reviews in Oncology/Hematology, Pharmacogenomics and Future Oncology.

In The Last Decade

Elissar Moujaess

9 papers receiving 308 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elissar Moujaess Lebanon	6	226	89	39	38	35	9	318
Chiara Citterio Italy	12	221 1.0×	143 1.6×	98 2.5×	24 0.6×	24 0.7×	47	381
Hagar Elghazawy Egypt	9	182 0.8×	62 0.7×	60 1.5×	23 0.6×	34 1.0×	19	284
Stephanie Smits United Kingdom	10	224 1.0×	114 1.3×	93 2.4×	34 0.9×	21 0.6×	20	474
Navpreet Rana United States	5	180 0.8×	98 1.1×	41 1.1×	27 0.7×	23 0.7×	16	282
Abdullah A. Alsharm Saudi Arabia	6	209 0.9×	31 0.3×	46 1.2×	25 0.7×	24 0.7×	18	307
Ash Kieran Clift United Kingdom	7	86 0.4×	48 0.5×	26 0.7×	18 0.5×	36 1.0×	10	230
Jana Ihlow Germany	8	80 0.4×	195 2.2×	48 1.2×	22 0.6×	19 0.5×	26	363
Adam Lee United States	8	92 0.4×	157 1.8×	85 2.2×	28 0.7×	11 0.3×	32	359
Kasra Kolahdouzan Iran	11	83 0.4×	60 0.7×	55 1.4×	17 0.4×	36 1.0×	27	285
Viswatej Avutu United States	7	250 1.1×	94 1.1×	74 1.9×	15 0.4×	22 0.6×	21	331

Countries citing papers authored by Elissar Moujaess

Since Specialization

Citations

This map shows the geographic impact of Elissar Moujaess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elissar Moujaess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elissar Moujaess more than expected).

Fields of papers citing papers by Elissar Moujaess

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elissar Moujaess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elissar Moujaess. The network helps show where Elissar Moujaess may publish in the future.

Co-authorship network of co-authors of Elissar Moujaess

This figure shows the co-authorship network connecting the top 25 collaborators of Elissar Moujaess. A scholar is included among the top collaborators of Elissar Moujaess based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elissar Moujaess. Elissar Moujaess is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Moujaess, Elissar, et al.. (2021). Immune Checkpoint Inhibitors for Advanced or Metastatic Basal Cell Carcinoma: How much Evidence do we Need?. Immunotherapy. 13(15). 1293–1304. 5 indexed citations

Moujaess, Elissar, et al.. (2021). Cancer management during the COVID-19 pandemic: Choosing between the devil and the deep blue sea. Critical Reviews in Oncology/Hematology. 167. 103273–103273. 14 indexed citations

Moujaess, Elissar, Hampig Raphaël Kourié, Chris Labaki, et al.. (2021). Perceptions of the COVID-19 vaccine Among Patients With Cancer: A Single-Institution Survey. Future Oncology. 17(31). 4071–4079. 33 indexed citations

Kourié, Hampig Raphaël, et al.. (2021). Molecular Pathogenesis of Hereditary Lung Cancer: a Literature Review. Pharmacogenomics. 22(12). 791–803. 3 indexed citations

Moujaess, Elissar, Hampig Raphaël Kourié, & Marwan Ghosn. (2020). Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Critical Reviews in Oncology/Hematology. 150. 102972–102972. 155 indexed citations

Moujaess, Elissar, et al.. (2020). Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. Critical Reviews in Oncology/Hematology. 157. 103169–103169. 16 indexed citations

Haddad, Fadi, et al.. (2020). Poly-(ADP-ribose) Polymerase Inhibitors: Paradigm Shift in the First-Line Treatment of Newly Diagnosed Advanced Ovarian Cancer. Pharmacogenomics. 21(10). 721–727. 5 indexed citations

Moujaess, Elissar, Fadi Haddad, Roland Eid, & Hampig Raphaël Kourié. (2019). The Emerging Use of Immune Checkpoint Blockade in the Adjuvant Setting for Solid Tumors: A Review. Immunotherapy. 11(16). 1409–1422. 34 indexed citations

Moujaess, Elissar, May Fakhoury, Tarek Assi, et al.. (2017). The Therapeutic use of human albumin in cancer patients’ management. Critical Reviews in Oncology/Hematology. 120. 203–209. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact